Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study

Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study

Newer methodologies are needed to assess the real-world comparative effectiveness of a “generation” of pharmaceutical innovation versus the prior standard of care. This chart review study aimed to first evaluate the cumulative clinical benefits of pharmaceutical innovation in everyday relapse/refrac...

Full description

Bibliographic Details
Main Authors: Ioannis Petrakis, Christos Kontogiorgis, Evangelia Nena, Sosana Delimpasi, Natasa E. Loutsidi, Emmanouil Spanoudakis, Stergios Intzes, Christina Misidou, Marianthi Symeonidou, Nikolaos Giannakoulas, Theodoros C. Constantinidis, Evangelos Terpos
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Cancers
Subjects:
carfilzomib
daratumumab
ixazomib
pomalidomide
multiple myeloma
real world
Online Access:https://www.mdpi.com/2072-6694/15/24/5846

Internet

https://www.mdpi.com/2072-6694/15/24/5846

Similar Items